Menu

Wellcome Sanger Institute Leaders Accused of Bullying

Several members of senior management at the prestigious UK research center face claims of sexism and mistreatment of staff.

Sep 4, 2018
Jef Akst

Update (October 30): An investigation by an independent lawyer “failings found in the way in which people have been managed,” but cleared Wellcome Sanger Institute Director Mike Stratton of discrimination, harassment, and misuse of funds, Nature reports.

ABOVE: WIKIMEDIA, MAGNUS MANSKE

The Wellcome Trust will be looking into several members of upper-level management at its Sanger Institute in Cambridge, UK, including director Sir Michael Stratton, regarding a suite of allegations from 10 former and current staff members. Claims include bullying and mistreatment, pressuring employees to quit, and not investigating grievances—problems, the complainants say, that female staff face more commonly than male staff do. 

Many of the complaints concern the turnover of staff at Sanger. The Guardian reports that the institution stands to lose some 25 percent of its faculty, including high-level positions such as the chief of scientific operations, within a year of receiving a regular five-year grant of more than £400 million (nearly $515 million). Staff have spoken out about the quick departure of many employees, who are sometimes asked to sign confidentiality agreements. “Many successful and high-profile scientists are reported to be in the category of leaving or have left the institute,” one former staff member told The Guardian anonymously.

See “Wellcome Trust Makes Reporting Harassment Mandatory

Earlier this year, the Wellcome Trust announced a new anti-bullying policy that would penalize institutions that didn’t report misconduct and defund researchers who have been found to have mistreated coworkers. Last month, geneticist Nazneen Rahman resigned from the Institute of Cancer Research (ICR) after being sanctioned by this new rule for harassment of her colleagues. 

See “Cancer Geneticist Quits After Harassment Allegations

Correction (September 4): The original version of this story stated that the Sanger Institute could lose 25 percent of its staff. Rather, the research center could lose 25 percent of its faculty. The Scientist regrets the error.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.

Thermo Fisher Scientific: Freezers for Biological Samples

Thermo Fisher Scientific: Freezers for Biological Samples

Fluctuations in temperature can reduce the efficacy, decompose, or shorten the shelf life of biologics. Therefore, it is important to store biologics at the right temperature using standardized protocols.